AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain.
5 affiliations
- 1Department of Pain Management, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.
- 2Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.
- 3Tumor Immunology and Cytotherapy of Medical Research Center, Shandong Provincial Key Laboratory of Clinical Research for Pancreatic Diseases, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.
- 4Department of Obstetrics, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.
- 5Department of Spine Surgery, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266000, China.
Abstract
Neuropathic pain (NP) remains a major clinical challenge as current medications are ineffective in treating the underlying cause, and the clinical use of these drugs also has adverse reactions such as addiction. Therefore, specialized pro-resolving mediators (SPMs) may represent a promising therapeutic strategy. Microglia-mediated neuroinflammation is central to NP pathogenesis, yet feasible strategies for precise modulation of microglial inflammatory responses remain limited. Here, we reveal that aspirin-triggered resolvin D1 (AT-RvD1) promotes a shift of microglia toward an anti-inflammatory and pro-repair state via a novel ANGPTL4-SUCLG1-propionate axis, consequently attenuating neuroinflammation and pain hypersensitivity in mice models with NP. To address invasive nature of intrathecal injection limitation in NP clinical treatment, an MG1 peptide-modified liposomal delivery system encapsulating AT-RvD1 (AT-RvD1@Lipo-MG1) is developed. Intravenous administration of this nanoplatform enables effective and targeted delivery of AT-RvD1 to spinal microglia, with robust analgesic and anti-inflammatory effects and favorable biosafety in vivo. This study elucidates a novel mechanism through which AT-RvD1 modulates microglial inflammatory responses and proposes a highly translatable nanotherapeutic strategy for the treatment of NP.
Related
- Vehicle Optimization of Topical Clobetasol Propionate in Disseminated Granuloma Annulare: Clinical Insights From Two Cases
- Protective Effects of Achyranthes bidentata Root Extract Against Benign Prostatic Hyperplasia Induced by Testosterone Propionate in Rats
- Topical Fluticasone Propionate Versus Fusidic Acid for Zoon’s Balanitis in Men: A Prospective, Open-Label, Non-Randomised Comparative Study with an Exploratory Long-Term Assessment
- Perivascular injection of a pH-responsive and protease-degradable hydrogel with rapamycin-loaded liposomes inhibits neointimal hyperplasia after carotid wire injury in mice
- Visceral metastatic angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol
BibTeX
@article{wu2026atrvd1,
title = {{AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain.}},
author = {Kaili Wu and Chao Gao and Shunli Fu and Yan Li and Zhaohui Li and Xinyi Han and Yun Zhang and Yingqi Zhang and Yihao Wang},
journal = {Materials today. Bio},
year = {2026},
month = oct,
doi = {10.1016/j.mtbio.2026.103726},
url = {https://europepmc.org/article/MED/42898631},
note = {CC BY},
}
RIS
TY - JOUR
TI - AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain.
AU - Kaili Wu
AU - Chao Gao
AU - Shunli Fu
AU - Yan Li
AU - Zhaohui Li
AU - Xinyi Han
AU - Yun Zhang
AU - Yingqi Zhang
AU - Yihao Wang
PY - 2026
DA - 2026/10/05
JO - Materials today. Bio
DO - 10.1016/j.mtbio.2026.103726
UR - https://europepmc.org/article/MED/42898631
AB - Neuropathic pain (NP) remains a major clinical challenge as current medications are ineffective in treating the underlying cause, and the clinical use of these drugs also has adverse reactions such as addiction. Therefore, specialized pro-resolving mediators (SPMs) may represent a promising therapeutic strategy. Microglia-mediated neuroinflammation is central to NP pathogenesis, yet feasible strategies for precise modulation of microglial inflammatory responses remain limited. Here, we reveal that aspirin-triggered resolvin D1 (AT-RvD1) promotes a shift of microglia toward an anti-inflammatory and pro-repair state via a novel ANGPTL4-SUCLG1-propionate axis, consequently attenuating neuroinflammation and pain hypersensitivity in mice models with NP. To address invasive nature of intrathecal injection limitation in NP clinical treatment, an MG1 peptide-modified liposomal delivery system encapsulating AT-RvD1 (AT-RvD1@Lipo-MG1) is developed. Intravenous administration of this nanoplatform enables effective and targeted delivery of AT-RvD1 to spinal microglia, with robust analgesic and anti-inflammatory effects and favorable biosafety in vivo. This study elucidates a novel mechanism through which AT-RvD1 modulates microglial inflammatory responses and proposes a highly translatable nanotherapeutic strategy for the treatment of NP.
SN - 2590-0064
ER -